RNA interference improves myopathic phenotypes in mice over-expressing FSHD region gene 1 (FRG1)

Molecular Therapy

Volumn 19, Issue 11, 2011, Pages 2048-2054

  Wallace, Lindsay M ^a,b   Garwick Coppens, Sara E ^b   Tupler, Rossella ^c,d   Harper, Scott Q ^a,b,e  

^a OHIO STATE UNIVERSITY   (United States)

^b THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY REGION GENE 1 PROTEIN; GENE PRODUCT; MICRORNA; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY REGION GENE 1; GENE; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MOLECULAR CLONING; MOUSE; MUSCLE MASS; MUSCLE STRENGTH; NEWBORN; NONHUMAN; PHENOTYPE; RNA INTERFERENCE; VIRAL GENE DELIVERY SYSTEM;

MUS;

EID: 80455164692     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.118     Document Type: Article

References (45)

1. Koenig, M, Hoffman, E P, Bertelson, CJ, Monaco, AP, Feener, C and Kunkel, LM (1987). Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50: 509-517. (Pubitemid 18098338)
2. Scott, JM, Li, S, Harper, SQ, Welikson, R, Bourque, D, DelloRusso, C et al. (2002). Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin. Neuromuscul Disord 12 Suppl 1: S23-S29. (Pubitemid 36158767)
3. Lim, LE and Campbell, KP (1998). The sarcoglycan complex in limb-girdle muscular dystrophy. Curr Opin Neurol 11: 443-452. (Pubitemid 28542978)
4. Li, J, Dressman, D, Tsao, Y P, Sakamoto, A, Hoffman, EP and Xiao, X (1999). rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy. Gene Ther 6: 74-82. (Pubitemid 29043696)
5. Cordier, L, Hack, AA, Scott, MO, Barton-Davis, ER, Gao, G, Wilson, JM et al. (2000). Rescue of skeletal muscles of gamma-sarcoglycan-defcient mice with adeno-associated virus-mediated gene transfer. Mol Ther 1: 119-129.
6. Harper, SQ, Hauser, MA, DelloRusso, C, Duan, D, Crawford, RW, Phelps, SF et al. (2002). Modular fexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 8: 253-261. (Pubitemid 34250103)
7. Goyenvalle, A, Vulin, A, Fougerousse, F, Leturcq, F, Kaplan, JC, Garcia, L et al. (2004). Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306: 1796-1799. (Pubitemid 39601401)
8. Gregorevic, P, Blankinship, MJ, Allen, JM, Crawford, RW, Meuse, L, Miller, DG et al. (2004). Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 10: 828-834. (Pubitemid 39070856)
9. Mah, C, Pacak, CA, Cresawn, KO, Deruisseau, LR, Germain, S, Lewis, MA et al. (2007). Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. Mol Ther 15: 501-507.
10. Pacak, CA, Walter, GA, Gaidosh, G, Bryant, N, Lewis, MA, Germain, S et al. (2007). Long-term skeletal muscle protection after gene transfer in a mouse model of LGMD-2D. Mol Ther 15: 1775-1781. (Pubitemid 47434183)
11. Yue, Y, Ghosh, A, Long, C, Bostick, B, Smith, BF, Kornegay, JN et al. (2008). A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther 16: 1944-1952.
12. Kota, J, Handy, CR, Haidet, AM, Montgomery, CL, Eagle, A, Rodino-Klapac, LR et al. (2009). Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med 1: 6ra15.
13. Rodino-Klapac, LR, Montgomery, CL, Mendell, JR and Chicoine, LG (2011). AAV-mediated gene therapy to the isolated limb in rhesus macaques. Methods Mol Biol 709: 287-298.
14. Mendell, JR, Rodino-Klapac, LR, Rosales, XQ, Coley, BD, Galloway, G, Lewis, S et al. (2010). Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 68: 629-638.
15. Wallace LM, Garwick SE and Harper SQ (2010). RNAi therapy for dominant muscular dystrophies and other myopathies. In: Duan D (ed). Muscle Gene Therapy. Springer, New York: pp. 99-115.
16. Boudreau, RL and Davidson, BL (2010). RNAi therapeutics for CNS disorders. Brain Res 1338: 112-121.
17. Gabellini, D, D'Antona, G, Moggio, M, Prelle, A, Zecca, C, Adami, R et al. (2006). Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1. Nature 439: 973-977. (Pubitemid 43292415)
18. Bosnakovski, D, Xu, Z, Gang, EJ, Galindo, CL, Liu, M, Simsek, T et al. (2008). An isogenetic myoblast expression screen identifes DUX4-mediated FSHD-associated molecular pathologies. EMBO J 27: 2766-2779.
19. Dixit, M, Ansseau, E, Tassin, A, Winokur, S, Shi, R, Qian, H et al. (2007). DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Proc Natl Acad Sci USA 104: 18157-18162. (Pubitemid 350210837)
20. Gabellini, D, Green, MR and Tupler, R (2002). Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell 110: 339-348.
21. Kowaljow, V, Marcowycz, A, Ansseau, E, Conde, CB, Sauvage, S, Mattéotti, C et al. (2007). The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. Neuromuscul Disord 17: 611-623. (Pubitemid 47030917)
22. Lemmers, RJ, Van Der Vliet, PJ, Klooster, R, Sacconi, S, Camaño, P, Dauwerse, JG et al. (2010). A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 329: 1650-1653.
23. Wallace, LM, Garwick, SE, Mei, W, Belayew, A, Coppee, F, Ladner, KJ et al. (2011). DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo. Ann Neurol 69: 540-552.
24. Harper, SQ, Staber, PD, He, X, Eliason, SL, Martins, IH, Mao, Q et al. (2005). RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 102: 5820-5825. (Pubitemid 40559643)
25. INSERM and French Ministry of Health (2008) Prevalence of Rare Diseases: Bibliographic Data. In Orphanet Report: http://orpha.net/orphacom/cahiers/docs/ GB/Prevalence-of-rare-diseases-by-alphabetical-list.pdf.
26. Arashiro, P, Eisenberg, I, Kho, AT, Cerqueira, AM, Canovas, M, Silva, HC et al. (2009). Transcriptional regulation differs in affected facioscapulohumeral muscular dystrophy patients compared to asymptomatic related carriers. Proc Natl Acad Sci USA 106: 6220-6225.
27. Bodega, B, Ramirez, GD, Grasser, F, Cheli, S, Brunelli, S, Mora, M et al. (2009). Remodeling of the chromatin structure of the facioscapulohumeral muscular dystrophy (FSHD) locus and upregulation of FSHD-related gene 1 (FRG1) expression during human myogenic differentiation. BMC Biol 7: 41.
28. Celegato, B, Capitanio, D, Pescatori, M, Romualdi, C, Pacchioni, B, Cagnin, S et al. (2006). Parallel protein and transcript profles of FSHD patient muscles correlate to the D4Z4 arrangement and reveal a common impairment of slow to fast fbre differentiation and a general deregulation of MyoD-dependent genes. Proteomics 6: 5303-5321. (Pubitemid 44547168)
29. Hanel, ML, Wuebbles, RD and Jones, PL (2009). Muscular dystrophy candidate gene FRG1 is critical for muscle development. Dev Dyn 238: 1502-1512.
30. Liu, Q, Jones, TI, Tang, VW, Brieher, WM and Jones, PL (2010). Facioscapulohumeral muscular dystrophy region gene-1 (FRG-1) is an actin-bundling protein associated with muscle-attachment sites. J Cell Sci 123(Pt 7): 1116-1123.
31. Osborne, RJ, Welle, S, Venance, SL, Thornton, CA and Tawil, R (2007). Expression profle of FSHD supports a link between retinal vasculopathy and muscular dystrophy. Neurology 68: 569-577.
32. Reed, PW, Corse, AM, Porter, NC, Flanigan, KM and Bloch, RJ (2007). Abnormal expression of mu-crystallin in facioscapulohumeral muscular dystrophy. Exp Neurol 205: 583-586. (Pubitemid 46755775)
33. Van Deutekom, JC, Lemmers, RJ, Grewal, PK, Van Geel, M, Romberg, S, Dauwerse, HG et al. (1996). Identifcation of the frst gene (FRG1) from the FSHD region on human chromosome 4q35. Hum Mol Genet 5: 581-590. (Pubitemid 26141270)
34. Winokur, ST, Barrett, K, Martin, JH, Forrester, JR, Simon, M, Tawil, R et al. (2003). Facioscapulohumeral muscular dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxidative stress. Neuromuscul Disord 13: 322-333. (Pubitemid 36966161)
35. Winokur, ST, Chen, YW, Masny, PS, Martin, JH, Ehmsen, JT, Tapscott, SJ et al. (2003). Expression profling of FSHD muscle supports a defect in specifc stages of myogenic differentiation. Hum Mol Genet 12: 2895-2907. (Pubitemid 37442018)
36. Wuebbles, RD, Hanel, ML and Jones, PL (2009). FSHD region gene 1 (FRG1) is crucial for angiogenesis linking FRG1 to facioscapulohumeral muscular dystrophy-associated vasculopathy. Dis Model Mech 2: 267-274.
37. Van Der Maarel, SM, Frants, RR and Padberg, GW (2007). Facioscapulohumeral muscular dystrophy. Biochim Biophys Acta 1772: 186-194. (Pubitemid 46123910)
38. Snider, L, Asawachaicharn, A, Tyler, AE, Geng, LN, Petek, LM, Maves, L et al. (2009). RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy. Hum Mol Genet 18: 2414-2430.
39. Merlini, L, Carbone, I, Capanni, C, Sabatelli, P, Tortorelli, S, Sotgia, F et al. (2002). Familial isolated hyperCKaemia associated with a new mutation in the caveolin-3 (CAV-3) gene. J Neurol Neurosurg Psychiatr 73: 65-67. (Pubitemid 34713016)
40. Minetti, C, Sotgia, F, Bruno, C, Scartezzini, P, Broda, P, Bado, M et al. (1998). Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 18: 365-368. (Pubitemid 28158166)
41. Traverso, M, Gazzerro, E, Assereto, S, Sotgia, F, Biancheri, R, Stringara, S et al. (2008). Caveolin-3 T78M and T78K missense mutations lead to different phenotypes in vivo and in vitro. Lab Invest 88: 275-283. (Pubitemid 351311278)
42. Rodriguez-Lebron, E and Paulson, HL (2006). Allele-specifc RNA interference for neurological disease. Gene Ther 13: 576-581.
43. McBride, JL, Boudreau, RL, Harper, SQ, Staber, PD, Monteys, AM, Martins, I et al. (2008). Artifcial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 105: 5868-5873. (Pubitemid 351758464)
44. Harper, SQ, Staber, PD, Beck, CR, Fineberg, SK, Stein, C, Ochoa, D et al. (2006). Optimization of feline immunodefciency virus vectors for RNA interference. J Virol 80: 9371-9380. (Pubitemid 44435616)
45. Hanel, ML, Sun, CY, Jones, TI, Long, SW, Zanotti, S, Milner, D et al. (2011). Facioscapulohumeral muscular dystrophy (FSHD) region gene 1 (FRG1) is a dynamic nuclear and sarcomeric protein. Differentiation 81: 107-118.